Midaflur (INN; developmental code EXP 338) is a synthetic chemical compound classified as a 3-imidazoline derivative. It was developed in the late 1960s and possesses central skeletal muscle relaxant and sedative properties in humans and other mammals. The compound exhibits consistently high oral bioavailability and a long duration of action.
Pharmacology
While its pharmacodynamics remain poorly understood, midaflur has been observed to resemble meprobamate and pentobarbital in terms of its effects, while being considerably more potent. Preclinical studies indicated that midaflur had minimal effects at high doses in cardiovascular assessments.
Chemical Properties
- IUPAC name: 2,2,5,5-Tetrakis(trifluoromethyl)-2,5-dihydro-1H-imidazol-4-amine
- Molecular formula: C₇H₃F₁₂N₃
- Molar mass: 357.103 g·mol⁻¹
- CAS Number: 23757-42-8
- UNII: 840CTL676L
History and Development
Midaflur was investigated for its potential as a central nervous system agent with anticonvulsant effects. Clinical research included a 1967 study by Levine et al. evaluating its effect on spasticity, and a 1971 pharmacology and toxicology study by Clark et al. It was developed as an anesthetic agent and acted as a central skeletal muscle relaxant with sedative properties.
Safety and Toxicology
According to available data, midaflur is toxic by ingestion, intraperitoneal, and intravenous routes. It has been identified as an experimental teratogen with other experimental reproductive effects. When heated to decomposition, it emits toxic fumes of fluorine and nitrogen oxides.
